28. ALPHAVAX (HSV1 & 2 ?)(2025): This comes directly from their website: AlphaVax is developing prophylactic and therapeutic alphavaccine products focused on the sexually transmitted form of HSV. These products are leveraged by 6 years of preclinical work showing excellent prophylactic protection in animal models as well as the ability to reduce HSV reactivation and disease severity in state-of-the-art therapeutic disease models. A successful prophylactic vaccine product is expected to require the induction of both antibody and T-cells, which makes HSV an ideally suited target for our alphavaccine platform. Based on successful preclinical work which is now published, AlphaVax is advancing an HSV alphavaccine into clinical testing early in 2010. Following phase 1 safety and immunogenicity trials, a phase 2 proof-of-concept trial may be carried out in “discordant couples” which should provide an early indication of efficacy. I’m not sure what the holdup on taking this to trials, but suspect it is money, they are currently looking for partners. The latest news I have on this vaccine is dated November 4, 2009:
http://www.alphavax.com/docs/pr/release_59.pdf妈呀,要2025年啊,哎,时间太久了。